Nektar Considers New Phase III Designs For NKTR-181 After Phase II Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Mu-opioid analgesic NKTR-181 fails primary endpoint in Phase II study due to response in placebo arm. Undeterred, Nektar says it will be moving the drug to Phase III and plans to talk to FDA about alternative options for trial design.